Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19).
Mayo Clin Proc
; 95(6): 1213-1221, 2020 06.
Article
in English
| MEDLINE | ID: covidwho-1450185
ABSTRACT
As the coronavirus disease 19 (COVID-19) global pandemic rages across the globe, the race to prevent and treat this deadly disease has led to the "off-label" repurposing of drugs such as hydroxychloroquine and lopinavir/ritonavir, which have the potential for unwanted QT-interval prolongation and a risk of drug-induced sudden cardiac death. With the possibility that a considerable proportion of the world's population soon could receive COVID-19 pharmacotherapies with torsadogenic potential for therapy or postexposure prophylaxis, this document serves to help health care professionals mitigate the risk of drug-induced ventricular arrhythmias while minimizing risk of COVID-19 exposure to personnel and conserving the limited supply of personal protective equipment.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Long QT Syndrome
/
Torsades de Pointes
/
Death, Sudden, Cardiac
/
Ritonavir
/
Risk Adjustment
/
Lopinavir
/
Hydroxychloroquine
Type of study:
Observational study
/
Prognostic study
Language:
English
Journal:
Mayo Clin Proc
Year:
2020
Document Type:
Article
Affiliation country:
J.mayocp.2020.03.024
Similar
MEDLINE
...
LILACS
LIS